Certara Appoints Patrick F. Smith to President of Integrated Drug Development

Princeton, N.J., October 12, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Patrick F. Smith, Pharm.D. as president of Integrated Drug Development (IDD), reporting to CEO William F. Feehery.  Dr. Smith will lead the Company’s global drug development services team, which creates value for clients across the … Continued

Certara Appoints Drayton T. Virkler as Chief Commercial Officer

Experienced commercial leader brings 20 years of experience in pharma Princeton, N.J., October 5, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Drayton T. Virkler to the newly created position of Chief Commercial Officer. In this role, Mr. Virkler will drive the Company’s global commercial strategy and … Continued

Certara Senior Scientific Leader Receives 2021 Leadership Award by International Society of Pharmacometrics

Recognizes those who have advanced the field of pharmacometrics and its future direction PRINCETON, NJ.— October 4, 2021 – Certara, Inc., the global leader in biosimulation, today announced that Piet van der Graaf, Pharm.D., Ph.D,. is the recipient of the 2021 Leadership Award by the International Society of Pharmacometrics (ISoP) for his outstanding sustained leadership, … Continued

Certara Completes Acquisition of Pinnacle 21

Complementary technologies accelerate and help assure success in the drug development process Princeton, N.J., October 4, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the completion of the previously announced transaction to acquire Pinnacle 21, a leading provider of SaaS solutions for clinical data fitness, regulatory compliance and submission readiness.  … Continued

Certara Launches New Synchrogenix™ Writer Software to Accelerate the Regulatory Submission Process

Cloud-based and validated regulatory software automates and advances quality of patient narratives Princeton, N.J., September 30, 2021 – Certara, a global leader in biosimulation, today announced the launch of Synchrogenix™ Writer, a new regulatory SaaS product that expedites the authoring and review of patient narratives. Patient narratives describe adverse events or adverse drug reactions and … Continued

Certara Announces New Clinical Science Group and Adds Senior Scientific Experts

Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities PRINCETON, N.J.— September 22, 2021. Certara, a global leader in biosimulation, today announced that it is expanding its Integrated Drug Development (IDD) division with a new clinical science group, headed up by Philippa Marshall, M.D., Vice President of Clinical Science.  The Company also appointed David Mitchell, … Continued

Certara Awarded FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation

Represents Fourth FDA Grant for Simcyp MechDermA Model for Virtual Bioequivalence PRINCETON, N.J.— September 20, 2021. Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the Company has been awarded a grant from the U.S. Food and Drug Administration (FDA) to verify and expand biosimulation models for assessing virtual bioequivalence (VBE) to help enable … Continued

Certara Announces Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

PRINCETON, N.J.— September 13, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it closed its public offering of 23,000,000 shares of common stock at $31.00 per share. The closing includes 3,000,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. Certara sold … Continued

Certara Announces Pricing of Public Offering of Common Stock

PRINCETON, N.J.—September 8, 2021. Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of shares of its common stock by Certara and certain existing stockholders (“the selling stockholders”) at a price to the public of $31.00 per share. Certara is offering 4.5 million shares of its … Continued

1 of 27
Back to top
Powered by Translations.com GlobalLink OneLink Software